



Glioblastoma in Adults: Current Management and Future Directions

Guest Editors:

Dr. Thomas Graillon

Department of Neurosurgery,
Hospital La Timone, Aix Marseille
Univ, APHM, Marseille, France

Dr. Sebastien Boissonneau

Department of Neurosurgery,
Hospital La Timone, Aix Marseille
Univ, APHM, Marseille, France

Deadline for manuscript
submissions:


closed (31 October 2023)

Message from the Guest Editors

Dear Colleagues,

As you know, glioma is the most common primary tumor of the central nervous system, and is characterized by rapid growth and aggressiveness; glioblastoma is one of the most dreaded brain tumors. There has been a commitment to drug development and new treatments for glioma, but progress has been limited, and the prognosis for patients with GBM remains poor. Inherent or acquired resistance to existing therapies, regional and heterogeneous blood glioma barriers, and the number of stem-cell-like cells within glioblastomas are challenges that are being actively addressed. These new approaches need to be summarized, especially regarding fundamental oncology approaches, and in the light of the new WHO brain tumor classification of 2021.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase,** and **other databases.**

Journal Rank: JCR - Q2 (*Oncology*)

Contact Us

Current Oncology Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/currenncol
currentoncology@mdpi.com
[X@CurrentOncology](https://twitter.com/CurrentOncology)